Despite having higher outpatient costs, hydroxyurea treatment for children with sickle cell anemia had a 21% lower total estimated annual cost than placebo, according to a study in the journal Pediatrics. The hydroxyurea group had fewer hospitalizations compared with the placebo group, but both had similar lengths of stay.

Full Story:

Related Summaries